Physician profile
Rohit J Parmar
NPI 1114985405
$3,168.03
in general payments reported to CMS, 2019-2025
23 companies · $303 in 2025
The $303 reported for 2025 was less than what a typical Nuclear Cardiology provider received nationally (typical 2025 total: $434).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $276 · 2020: $108 · 2021: $439 · 2022: $630 · 2023: $828 · 2024: $584 · 2025: $303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,715.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $745.62 | 2019-2025 | |
| Amgen INC. | $513.23 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $356.10 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $289.38 | 2019-2025 | Camzyos, Eliquis |
| Heartflow, INC. | $167.88 | 2021-2023 | Ffrct |
| Medtronic, INC. | $163.40 | 2023-2025 | Corevalve Evolut R, Symplicity G3 |
| Novo Nordisk INC | $136.86 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Philips North America LLC | $127.69 | 2024-2025 | (Ck4) Mcot, Extended Holter, (Ck7) Extended Holter |
| Merck Sharp & Dohme LLC | $110.18 | 2021-2023 | Verquvo |
| Janssen Pharmaceuticals, INC | $92.77 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.87 | 2019-2023 | Jardiance |
| Kiniksa Pharmaceuticals, Ltd. | $75.96 | 2021-2023 | Arcalyst |
| Amarin Pharma, INC. | $74.75 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $67.68 | 2022-2025 | Lifevest |
| Arbor Pharmaceuticals, INC. | $43.59 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $23.08 | 2023 | |
| Kiniksa Pharmaceuticals International, Plc | $17.10 | 2024 | Arcalyst |
| Vital Connect, INC | $16.96 | 2025 | Vitalpatch Rtm |
| Cvrx, INC. | $16.17 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $15.12 | 2024 | Farxiga |
| Edwards Lifesciences Corporation | $13.71 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $12.45 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohit Parmar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.